Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate.
Hemicrania continua (HC) is an uncommon and under-recognized primary headache disorder characterized by a strictly unilateral continuous headache of moderate intensity with possible exacerbations and associated with ipsilateral autonomic features. HC has generally a prompt and enduring response to indomethacin although 25% to 50% of treated patients develop gastrointestinal side effects. These cases pose a difficult management challenge as no other drug is consistently effective in HC. Recently 2 HC patients responsive to topiramate treatment have been reported. Here we describe 2 more patients effectively treated with topiramate. Neither reported any side effects and one had persisting response for 6 months after drug withdrawal.
Brighina
Filippo
F
Department of Neurology, University of Palermo, Palermo, Italy.
Palermo
Antonio
A
Cosentino
Giuseppe
G
Fierro
Brigida
B
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005756:Gastritis / Q000139:chemically induced; D006261:Headache / Q000517:prevention & control*; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D019233:Retreatment; D000077236:Topiramate
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose; D007213:Indomethacin